Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Biliary Tract Diseases

Free Subscription Articles published in Hepatology Retrieve available abstracts of 168 articles: HTML format

Single Articles

October 2026
1. WASSMER CH, Gelli M, Wong TCL, Li Z, et al
   The rise of transplant oncology in primary liver cancer and metastatic disease.
   Hepatology. 2026;84:1181-1208.
   PubMed     Abstract available
   
   
   July 2026
2. SIDHU G
   Bile acids as the silent harbinger: Early signals of portal hypertension after "successful" Kasai.
   Hepatology. 2026;84:1-2.
   PubMed    
   
   
   May 2026
3. GERUSSI A, Sebode M, Nofit E, Stoelinga A, et al
   Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus.
   Hepatology. 2026 May 14. doi: 10.1097/HEP.0000000000001793.
   PubMed     Abstract available
   
   
   
4. KHAN S
   Survival in de novo perihilar cholangiocarcinoma: Does transplant outperform resection?
   Hepatology. 2026;83:1023-1024.
   PubMed    
   
   
   April 2026
5. MOL B, Trivedi PJ
   Interpreting surgical associations in primary sclerosing cholangitis: Caution in clinical messaging.
   Hepatology. 2026 Apr 6. doi: 10.1097/HEP.0000000000001766.
   PubMed    
   
   
   March 2026
6. ZHIXING L, Liu S, Yu H, Yuxi L, et al
   Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma.
   Hepatology. 2026 Mar 4. doi: 10.1097/HEP.0000000000001735.
   PubMed     Abstract available
   
   
   February 2026
7. CHEN S, Wan C, Yu C, Shen T, et al
   Dietary anthocyanins alleviates age-dependent hepatic steatosis by expanding Limosilactobacillus reuteri and modulating gut microbiota-bile acid-hepatic FXR signaling.
   Hepatology. 2026 Feb 24. doi: 10.1097/HEP.0000000000001721.
   PubMed     Abstract available
   
   
   
8. BITTERMANN T, Leonard CE
   Stains in primary biliary cholangitis: Untangling promise from bias.
   Hepatology. 2026 Feb 19. doi: 10.1097/HEP.0000000000001722.
   PubMed    
   
   
   
9. MARKAIDE E, Izquierdo-Sanchez L, Olaizola I, Urretabizkaia-Garmendia J, et al
   Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes.
   Hepatology. 2026 Feb 10. doi: 10.1097/HEP.0000000000001711.
   PubMed     Abstract available
   
   
   
10. WU CW, Lui RN
    Unravelling the immunogenetic architecture of cholangiocarcinoma.
    Hepatology. 2026 Feb 6. doi: 10.1097/HEP.0000000000001712.
    PubMed    
    
    
    
11. LEUNG KK, Li W, Hansen B, Gulamhusein A, et al
    Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort.
    Hepatology. 2026 Feb 4. doi: 10.1097/HEP.0000000000001692.
    PubMed     Abstract available
    
    
    
12. HAN Y, Byun J, VanLith CJ, Cooley MA, et al
    Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses.
    Hepatology. 2026 Feb 2. doi: 10.1097/HEP.0000000000001699.
    PubMed     Abstract available
    
    
    
13. CHOI J, Xu J, Nguyen VH, Przybyszewski E, et al
    Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study.
    Hepatology. 2026 Feb 2. doi: 10.1097/HEP.0000000000001701.
    PubMed     Abstract available
    
    
    
14. UDOMPAP P
    Metabolic syndrome and cholangiocarcinoma: A signal too strong to ignore.
    Hepatology. 2026;83:195-196.
    PubMed    
    
    
    January 2026
15. SABOROWSKI A, Peters S, Zhao J, Marhenke S, et al
    Stroma-driven inter- and intratumoral heterogeneity of PD-L1 expression in cholangiocarcinoma: Implications for biomarker development and prognostic evaluation.
    Hepatology. 2026 Jan 26. doi: 10.1097/HEP.0000000000001686.
    PubMed     Abstract available
    
    
    
16. DONG Y, Stumpf HE, Smoot RL, Starlinger PP, et al
    Anatomic subsets of cholangiocarcinoma: More different than alike.
    Hepatology. 2026 Jan 12. doi: 10.1097/HEP.0000000000001672.
    PubMed     Abstract available
    
    
    
17. WANG W, Yin S, Xu Q, Song D, et al
    Biologically interpretable deep learning-derived MRI phenotypes reveal lymph node involvement and neoadjuvant therapy response in intrahepatic cholangiocarcinoma.
    Hepatology. 2026 Jan 12. doi: 10.1097/HEP.0000000000001671.
    PubMed     Abstract available
    
    
    December 2025
18. WOO S, Kang B, Lee SH, Kim JS, et al
    Biology-driven stratification of advanced biliary tract cancer treated with nab-paclitaxel plus gemcitabine-cisplatin: A prospective observational cohort study.
    Hepatology. 2025 Dec 19. doi: 10.1097/HEP.0000000000001650.
    PubMed     Abstract available
    
    
    
19. XUN Z, Wang H, Xuan Z, Xiong K, et al
    Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level.
    Hepatology. 2025 Dec 10. doi: 10.1097/HEP.0000000000001641.
    PubMed     Abstract available
    
    
    
20. HUSSAIN N, Motta RV, Gungabissoon U, Casillas L, et al
    Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity.
    Hepatology. 2025 Dec 5. doi: 10.1097/HEP.0000000000001634.
    PubMed     Abstract available
    
    
    November 2025
21. XIE M, Wu H, Xu J
    Letter to the Editor: From risk alert to decision support: Enhancing the clinical value of the AI model for cholangiocarcinoma.
    Hepatology. 2025 Nov 11. doi: 10.1097/HEP.0000000000001610.
    PubMed    
    
    
    
22. SINGH Y, Eaton JE, Erickson BJ, Gores GJ, et al
    Reply: From risk alert to decision support: Enhancing the clinical value of the AI Model for cholangiocarcinoma.
    Hepatology. 2025 Nov 11. doi: 10.1097/HEP.0000000000001611.
    PubMed    
    
    
    October 2025
23. WEI T, Ma ZJ, Guo S, Weiss M, et al
    Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling.
    Hepatology. 2025 Oct 30. doi: 10.1097/HEP.0000000000001594.
    PubMed     Abstract available
    
    
    
24. WENG D, Huang G, Liu Y
    Letter to the Editor: Clarifying the relative contributions of collagen architecture and stiffness to antitumor immunity in GIONF-Enhanced PD-1 blockade for cholangiocarcinoma.
    Hepatology. 2025 Oct 29. doi: 10.1097/HEP.0000000000001598.
    PubMed    
    
    
    
25. GRIMAUD E, Gardin A, Ackermann O, Habes D, et al
    Serum bile acid levels predict the development of portal hypertension and high-risk esophageal varices following successful Kasai in biliary atresia.
    Hepatology. 2025 Oct 23. doi: 10.1097/HEP.0000000000001592.
    PubMed     Abstract available
    
    
    
26. XU M, Ju-Seog L
    Multi-omics and machine learning in cholangiocarcinoma: A paradigm shift toward molecular subtyping and precision therapy.
    Hepatology. 2025 Oct 2. doi: 10.1097/HEP.0000000000001560.
    PubMed    
    
    
    
27. MININI M, Avveduto G, Becharef S, Meunier-Thaens M, et al
    Laser-activated nanoparticles rewire tumor microenvironment enhancing PD-1 blockade and T cell response in cholangiocarcinoma.
    Hepatology. 2025 Oct 2. doi: 10.1097/HEP.0000000000001545.
    PubMed     Abstract available
    
    
    
28. HORST LJ, Kempski J, Walmsley M, Huber S, et al
    PSC and colitis: A complex relationship.
    Hepatology. 2025;82:960-984.
    PubMed     Abstract available
    
    
    September 2025
29. MUN DG, Jessen E, Tomlinson JL, Carlson D, et al
    Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic target.
    Hepatology. 2025 Sep 29. doi: 10.1097/HEP.0000000000001535.
    PubMed     Abstract available
    
    
    
30. TESINI G, Ibrahim H, Rimassa L, Braconi C, et al
    Evolving Precision: Updates in Targeted Therapy for Cholangiocarcinoma.
    Hepatology. 2025 Sep 22. doi: 10.1097/HEP.0000000000001541.
    PubMed     Abstract available
    
    
    
31. SIMBRUNNER B, Paternostro R, Reiberger T, Trauner M, et al
    Bile acid signaling in MASLD: from pathogenesis to therapeutic applications.
    Hepatology. 2025 Sep 19. doi: 10.1097/HEP.0000000000001539.
    PubMed     Abstract available
    
    
    
32. DONG Y, Li Z, Gores GJ, Heimbach JK, et al
    Reply: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma.
    Hepatology. 2025 Sep 10. doi: 10.1097/HEP.0000000000001521.
    PubMed    
    
    
    
33. LI Y, Fan X, Xu X
    Letter to the editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma.
    Hepatology. 2025 Sep 10. doi: 10.1097/HEP.0000000000001519.
    PubMed    
    
    
    
34. WILECHANSKY RM
    Surging sludge: Intrahepatic cholangiocarcinoma mortality on the rise worldwide.
    Hepatology. 2025;82:543-544.
    PubMed    
    
    
    August 2025
35. DING J, She HY, Cheng Y, Sun HY, et al
    A novel mechanism involving USP53-regulated BSEP trafficking underlies low-GGT intrahepatic cholestasis.
    Hepatology. 2025 Aug 19. doi: 10.1097/HEP.0000000000001501.
    PubMed     Abstract available
    
    
    
36. ZENG Q, Xie D, Zhou Q, Qian B, et al
    Letter to the Editor: The treatment options for de novo perihilar cholangiocarcinoma require more details.
    Hepatology. 2025 Aug 13. doi: 10.1097/HEP.0000000000001496.
    PubMed    
    
    
    
37. DONG Y, Li Z, Gores GJ, Heimbach JK, et al
    Reply: The treatment options for de novo perihilar cholangiocarcinoma require more details.
    Hepatology. 2025 Aug 13. doi: 10.1097/HEP.0000000000001497.
    PubMed    
    
    
    
38. ZHANG D, Yang Y, Lu Z
    Letter to the Editor: Biliary tract cancer subtype heterogeneity: An overlooked key analytic dimension.
    Hepatology. 2025 Aug 12. doi: 10.1097/HEP.0000000000001490.
    PubMed    
    
    
    July 2025
39. FAN G, Han X, Shi Y
    Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 30. doi: 10.1097/HEP.0000000000001480.
    PubMed    
    
    
    
40. TAKEFUJI Y
    Letter to the editor: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis.
    Hepatology. 2025 Jul 29. doi: 10.1097/HEP.0000000000001479.
    PubMed    
    
    
    
41. APODAKA-BIGURI M, Simao AL, Gonzalez-Romero F, Mestre D, et al
    E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.
    Hepatology. 2025 Jul 28. doi: 10.1097/HEP.0000000000001461.
    PubMed     Abstract available
    
    
    
42. ABRUZZESE GA, Martinez-Chantar ML
    Minor players, major signals: Unveiling the systemic and gut-localized impact of microbial amidated bile acids in hepatopancreatobiliary disease.
    Hepatology. 2025 Jul 21. doi: 10.1097/HEP.0000000000001473.
    PubMed    
    
    
    
43. MARTINS A, Khakoo NS, Reddy A, Reynolds JM, et al
    Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis.
    Hepatology. 2025 Jul 15. doi: 10.1097/HEP.0000000000001465.
    PubMed     Abstract available
    
    
    
44. NOMDEN M, Kuipers F, Lexmond WS, Gu T, et al
    Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency.
    Hepatology. 2025 Jul 11. doi: 10.1097/HEP.0000000000001430.
    PubMed     Abstract available
    
    
    
45. DONG Y, Li Z, Podrascanin V, Eaton JE, et al
    Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001449.
    PubMed     Abstract available
    
    
    
46. GUO Y, Zhang Q, Li B, Dai W, et al
    Biliary YB-1/GLI2 axis facilitates ductular reaction and promotes hepatic stellate cell activation via SPP1/Integrin alphavbeta1 signaling during liver fibrogenesis.
    Hepatology. 2025 Jul 4. doi: 10.1097/HEP.0000000000001458.
    PubMed     Abstract available
    
    
    
47. KENNEDY L, Hargrove L, Demieville J, Karstens W, et al
    Retraction: Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2-/- mice and human cholangiocarcinoma tumorigenesis.
    Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001403.
    PubMed    
    
    
    
48. TRAUNER M, Karpen SJ, Dawson PA
    Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.
    Hepatology. 2025 Jul 2. doi: 10.1097/HEP.0000000000001438.
    PubMed     Abstract available
    
    
    
49. MANCINELLI R, Franchitto A, Glaser S, Meng F, et al
    Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8.
    Hepatology. 2025;82:E22.
    PubMed    
    
    
    
50. LI B, Ilyas SI
    The dynamic duo: How tumor-associated macrophages and tumor cells team up in cholangiocarcinoma.
    Hepatology. 2025;82:1-2.
    PubMed    
    
    
    
51. HAMMONS J, Warren EK, Wittling MC, Bennett FJ, et al
    Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma.
    Hepatology. 2025 Jul 1. doi: 10.1097/HEP.0000000000001439.
    PubMed     Abstract available
    
    
    June 2025
52. CHUNG BK, Jordens MS, Ogaard J, Reims HM, et al
    Multimodal transcriptomics identifies metallothionein as a novel pathway in primary sclerosing cholangitis.
    Hepatology. 2025 Jun 25. doi: 10.1097/HEP.0000000000001432.
    PubMed     Abstract available
    
    
    
53. TEMPRANO AG, Romero MR, Ghallab A, Llera L, et al
    Gut-to-Bile transfer of microbially amidated minor bile acids in patients with hepatopancreatobiliary disorders.
    Hepatology. 2025 Jun 23. doi: 10.1097/HEP.0000000000001441.
    PubMed     Abstract available
    
    
    
54. CARPINO G, Overi D, Macias RI, Cardinale V, et al
    Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement.
    Hepatology. 2025 Jun 16. doi: 10.1097/HEP.0000000000001425.
    PubMed     Abstract available
    
    
    
55. LI F, Li Y, Wang L, Xu L, et al
    Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001423.
    PubMed     Abstract available
    
    
    
56. BIAN Q, Wang S, Song Z, Liu F, et al
    Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice.
    Hepatology. 2025 Jun 9. doi: 10.1097/HEP.0000000000001422.
    PubMed     Abstract available
    
    
    
57. YAN B, Lai W, Wang Z
    Letter to the editor: Mitigating missing data bias and confounding on large-scale cohort studies of metabolic syndrome-cholangiocarcinoma associations.
    Hepatology. 2025 Jun 3. doi: 10.1097/HEP.0000000000001418.
    PubMed    
    
    
    May 2025
58. O'ROURKE CJ, Andersen JB
    Intrahepatic Cholangiocarcinoma PANoptosidy.
    Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001398.
    PubMed    
    
    
    April 2025
59. LEE MH
    Reply: Oversights in Stratification and Viral Screening- A Critical Appraisal of a MetS-Cholangiocarcinoma Cohort.
    Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001370.
    PubMed    
    
    
    
60. HUANG J
    Letter to the editor: Oversights in stratification and viral screening- A critical appraisal of a MetS-cholangiocarcinoma cohort.
    Hepatology. 2025 Apr 29. doi: 10.1097/HEP.0000000000001369.
    PubMed    
    
    
    
61. HOLMER M, Ingre M, Farkkila M, Ponsioen C, et al
    Cirrhosis and age are key determinants of HCC risk in individuals with primary sclerosing cholangitis: A multicenter longitudinal cohort study.
    Hepatology. 2025 Apr 16. doi: 10.1097/HEP.0000000000001351.
    PubMed     Abstract available
    
    
    
62. YU Y, You Y, Duan Y, Kang M, et al
    Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001352.
    PubMed     Abstract available
    
    
    
63. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
    Reply: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Apr 11. doi: 10.1097/HEP.0000000000001326.
    PubMed    
    
    
    
64. YANG LX, Gao Q, Shi JY, Wang ZC, et al
    Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
    Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274.
    PubMed    
    
    
    
65. SAMPLE JW
    A Niche Discovery: Spatial Mapping of Therapeutic Targets in Biliary Atresia.
    Hepatology. 2025;81:1109-1110.
    PubMed    
    
    
    
66. MOL B, Werner E, Culver EL, van der Meer AJ, et al
    Epidemiological and economical burden of cholestatic liver disease.
    Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001341.
    PubMed     Abstract available
    
    
    March 2025
67. GRONBAEK L, Vilstrup H, Jepsen P
    Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or common autoimmune penetrance?
    Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001325.
    PubMed    
    
    
    
68. LEVY C, Bowlus CL
    Erratum: Primary biliary cholangitis: Personalizing second-line therapies.
    Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001275.
    PubMed    
    
    
    
69. MACIAS RIR, Roessler S, Verstegen MMA
    Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Mar 24. doi: 10.1097/HEP.0000000000001322.
    PubMed    
    
    
    
70. CHEN TI, Chen MH, Yin SC, Lin CJ, et al
    Associations between metabolic syndrome and cholangiocarcinoma risk: A large-scale population-based cohort study.
    Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001312.
    PubMed     Abstract available
    
    
    
71. SINGH Y, Eaton JE, Venkatesh SK, Welle CL, et al
    Deep learning analysis of magnetic resonance imaging accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001314.
    PubMed     Abstract available
    
    
    
72. GORES GJ, Malhi H
    The dynamic landscape of cholestatic liver disease.
    Hepatology. 2025 Mar 7. doi: 10.1097/HEP.0000000000001298.
    PubMed    
    
    
    February 2025
73. HONG L, Mei J, Sun X, Wu Y, et al
    Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma.
    Hepatology. 2025 Feb 25. doi: 10.1097/HEP.0000000000001283.
    PubMed     Abstract available
    
    
    
74. CANCADO GGL, Deeb M, Gulamhusein AF
    Liver transplantation for cholestatic liver diseases: Timing & disease recurrence.
    Hepatology. 2025 Feb 17. doi: 10.1097/HEP.0000000000001268.
    PubMed     Abstract available
    
    
    
75. OLAIZOLA P, Olaizola I, Fernandez de Ara M, Lapitz A, et al
    Targeting protein hyperSUMOylation halts cholangiocarcinoma progression by impairing cancer cell viability and tumor-stroma crosstalk.
    Hepatology. 2025 Feb 11. doi: 10.1097/HEP.0000000000001259.
    PubMed     Abstract available
    
    
    
76. YU M, Sample JW, Yan IK, Takaichi S, et al
    Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models.
    Hepatology. 2025 Feb 10. doi: 10.1097/HEP.0000000000001256.
    PubMed     Abstract available
    
    
    
77. LI B
    BileMet: A new frontier in distinguishing malignant from benign biliary conditions.
    Hepatology. 2025;81:383-384.
    PubMed    
    
    
    January 2025
78. LI B, Ilyas SI
    Unveiling the immune landscape of IDH1-mutant cholangiocarcinoma: Pathways to new therapies.
    Hepatology. 2025 Jan 21. doi: 10.1097/HEP.0000000000001241.
    PubMed    
    
    
    
79. RONCA V, Davies SP, Oo YH, Lleo A, et al
    The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects.
    Hepatology. 2025 Jan 3. doi: 10.1097/HEP.0000000000001225.
    PubMed     Abstract available
    
    
    
80. IDALSOAGA F, Arab JP
    Unraveling bile acid dynamics in severe obesity.
    Hepatology. 2025;81:1-2.
    PubMed    
    
    
    December 2024
81. BITTERMANN T, Schaubel DE
    Obeticholic acid as second-line therapy for primary biliary cholangitis: Does target trial emulation solve the issue?
    Hepatology. 2024 Dec 20. doi: 10.1097/HEP.0000000000001198.
    PubMed    
    
    
    
82. THI VU Q, Nishimura Y, Harada K, Ito H, et al
    International trends in biliary tract cancer-related mortality, 2000-2022: An observational study of the World Health Organization mortality database.
    Hepatology. 2024 Dec 19. doi: 10.1097/HEP.0000000000001200.
    PubMed     Abstract available
    
    
    
83. LUO Y, Fraser L, Jezykowski J, Gupta NA, et al
    Interleukin 8-CXCR2 mediated neutrophil extracellular trap (NET) formation in biliary atresia associated with NET-Induced stellate cell activation.
    Hepatology. 2024 Dec 18. doi: 10.1097/HEP.0000000000001195.
    PubMed     Abstract available
    
    
    
84. CONDE DE LA ROSA L, Fabrega L, Torres S, Nunez S, et al
    Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity.
    Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001184.
    PubMed     Abstract available
    
    
    
85. ZABRANSKY DJ, Kartalia E, Lee JW, Leatherman JM, et al
    Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma.
    Hepatology. 2024 Dec 3. doi: 10.1097/HEP.0000000000001185.
    PubMed     Abstract available
    
    
    
86. BROOKHART MA, Mayne TJ, Coombs C, Breskin A, et al
    Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.
    Hepatology. 2024 Dec 2. doi: 10.1097/HEP.0000000000001174.
    PubMed     Abstract available
    
    
    November 2024
87. KARLSEN TH, Kaasen Jorgensen K, Bergquist A
    Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
    Hepatology. 2024 Nov 22. doi: 10.1097/HEP.0000000000001172.
    PubMed     Abstract available
    
    
    
88. LEVY C, Bowlus CL
    Primary Biliary Cholangitis: personalizing second-line therapies.
    Hepatology. 2024 Nov 12. doi: 10.1097/HEP.0000000000001166.
    PubMed     Abstract available
    
    
    October 2024
89. FAN G, Tao C, Li L, Xie T, et al
    The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma.
    Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001138.
    PubMed     Abstract available
    
    
    
90. CIRIA R, Ivanics T, Aliseda D, Claasen M, et al
    Liver transplantation for primary and secondary liver tumours. patient-level meta-analyses compared to unos conventional indications.
    Hepatology. 2024 Oct 28. doi: 10.1097/HEP.0000000000001129.
    PubMed     Abstract available
    
    
    
91. SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al
    Role of microbiome in autoimmune liver diseases.
    Hepatology. 2024;80:965-987.
    PubMed     Abstract available
    
    
    September 2024
92. JALAN-SAKRIKAR N, Guicciardi ME, O'Hara SP, Azad A, et al
    Central role for cholangiocyte pathobiology in cholestatic liver diseases.
    Hepatology. 2024 Sep 9. doi: 10.1097/HEP.0000000000001093.
    PubMed     Abstract available
    
    
    
93. CORNILLET M, Geanon D, Bergquist A, Bjorkstrom NK, et al
    Immunobiology of primary sclerosing cholangitis.
    Hepatology. 2024 Sep 2. doi: 10.1097/HEP.0000000000001080.
    PubMed     Abstract available
    
    
    August 2024
94. PANT K, Richard S, Peixoto E, Baral S, et al
    Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling.
    Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001055.
    PubMed     Abstract available
    
    
    
95. XIAO MH, Ma D, Wu S, Huang Z, et al
    Integrative single-cell and spatial transcriptomic analyses identify a pathogenic cholangiocyte niche and TNFRSF12A as therapeutic target for biliary atresia.
    Hepatology. 2024 Aug 23. doi: 10.1097/HEP.0000000000001064.
    PubMed     Abstract available
    
    
    
96. BJORNSSON ES, Devarbhavi HC
    Drug induced cholestatic liver diseases.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001052.
    PubMed     Abstract available
    
    
    
97. BANALES JM, Lapitz A, Fabris L
    Comparative performance of methylation DNA markers, brushing cytology, and FISH in diagnosing malignant biliary strictures.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001050.
    PubMed    
    
    
    July 2024
98. ZHANG X, Liu H, Cai P, Huang Z, et al
    Mdka produced by the activated HSCs drives bipotential progenitor cell redifferentiation during zebrafish biliary-mediated liver regeneration.
    Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001031.
    PubMed     Abstract available
    
    
    
99. SUTTON H, Sokol RJ, Kamath BM
    IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon?
    Hepatology. 2024 Jul 25. doi: 10.1097/HEP.0000000000001032.
    PubMed    
    
    
    
100. ZHUANG Y, Ortega-Ribera M, Szabo G
     Reply to: Exercise greater caution in bile acid research.
     Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001017.
     PubMed    
     
     
     
101. YI C, Chen L, Tao B, Wang X, et al
     Letter to the Editor: Exercise greater caution in bile acid research.
     Hepatology. 2024 Jul 17. doi: 10.1097/HEP.0000000000001013.
     PubMed    
     
     
     
102. ZHANG L, Xie P, Li M, Zhang X, et al
     Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.
     Hepatology. 2024 Jul 10. doi: 10.1097/HEP.0000000000001003.
     PubMed     Abstract available
     
     
     June 2024
103. ZHU M, Qu M, Lv S, Pan F, et al
     Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study.
     Hepatology. 2024 Jun 24. doi: 10.1097/HEP.0000000000000932.
     PubMed    
     
     
     
104. COOLEY MA, Schneider AR, Barr Fritcher EG, Milosevic D, et al
     Utility of methylated DNA markers for the diagnosis of malignant biliary strictures.
     Hepatology. 2024 Jun 21. doi: 10.1097/HEP.0000000000000970.
     PubMed     Abstract available
     
     
     
105. OH DY, Ikeda M, Lee CK, Rojas C, et al
     Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.
     Hepatology. 2024 Jun 14. doi: 10.1097/HEP.0000000000000965.
     PubMed     Abstract available
     
     
     
106. YANG S, Fu J, Qin W, Wang R, et al
     Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases.
     Hepatology. 2024 Jun 11. doi: 10.1097/HEP.0000000000000957.
     PubMed     Abstract available
     
     
     
107. HUANG YH, Loftfield E, Argirion I, Adami HO, et al
     Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project.
     Hepatology. 2024;79:1324-1336.
     PubMed     Abstract available
     
     
     
108. HANSEN BE, Vandriel SM, Vig P, Garner W, et al
     Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
     Hepatology. 2024;79:1279-1292.
     PubMed     Abstract available
     
     
     May 2024
109. AYDIN O, Wahlstrom A, de Jonge PA, Meijnikman AS, et al
     An integrated analysis of bile acid metabolism in humans with severe obesity.
     Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000938.
     PubMed     Abstract available
     
     
     
110. KELLERMAYER R, Carbone M, Horvath TD, Szigeti RG, et al
     Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune mediated liver injury.
     Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000926.
     PubMed     Abstract available
     
     
     April 2024
111. HITOMI Y, Ueno K, Aiba Y, Nishida N, et al
     A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis.
     Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000894.
     PubMed     Abstract available
     
     
     March 2024
112. JONES DE, Beuers U, Bonder A, Carbone M, et al
     Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
     Hepatology. 2024 Mar 22. doi: 10.1097/HEP.0000000000000864.
     PubMed     Abstract available
     
     
     
113. LAL BB, Alam S, Sibal A, Kumar K, et al
     Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency-related cholestasis.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000828.
     PubMed     Abstract available
     
     
     
114. AMPUERO J, Lucena A, Berenguer M, Hernandez-Guerra M, et al
     Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000826.
     PubMed     Abstract available
     
     
     
115. PANDURANGI S, Mourya R, Nalluri S, Fei L, et al
     Diagnostic accuracy of serum matrix metalloproteinase-7 as a biomarker of biliary atresia in a large North American cohort.
     Hepatology. 2024 Mar 6. doi: 10.1097/HEP.0000000000000827.
     PubMed     Abstract available
     
     
     
116. ZHUANG Y, Szabo G
     Reply to: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? more need to be known.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000816.
     PubMed    
     
     
     
117. KELLERER M, Javed S, Casar C, Will N, et al
     Antagonistic effects of the cytotoxic molecules granzyme B and TRAIL in the immunopathogenesis of sclerosing cholangitis.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000830.
     PubMed     Abstract available
     
     
     
118. JIANG L, Yang Z
     Letter to the Editor: How does bile acid-induced IRF3 phosphorylation mediate cholestatic liver and kidney injury? ---more need to be known.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000813.
     PubMed    
     
     
     
119. LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al
     Autoimmune diseases in primary sclerosing cholangitis and their first-degree relatives.
     Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000823.
     PubMed     Abstract available
     
     
     February 2024
120. ZHANG H, Zhu K, Zhang R, Guo Y, et al
     Oleic acid-PPARgamma-FABP4 loop fuels cholangiocarcinoma colonization in lymph node metastases microenvironment.
     Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000784.
     PubMed     Abstract available
     
     
     January 2024
121. WILBUR HC, Soares HP, Azad NS
     Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.
     Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000760.
     PubMed     Abstract available
     
     
     
122. BARGELLINI I, Rimassa L, Masi G
     SIRT and chemotherapy in unresectable iCCA: Ready to take off.
     Hepatology. 2024;79:9-11.
     PubMed    
     
     
     
123. CORPECHOT C, Lemoinne S, Soret PA, Hansen B, et al
     Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
     Hepatology. 2024;79:39-48.
     PubMed     Abstract available
     
     
     December 2023
124. CORPECHOT C, Lemoinne S, Soret PA, Chazouilleres O, et al
     Reply: Improving access to transient elastography data for Real-World Prognostic Applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000746.
     PubMed    
     
     
     
125. WIEGAND J, Franke A, Stein K, Trautwein C, et al
     Letter to the Editor: Improving access to transient elastography data for real-world prognostic applications in primary biliary cholangitis.
     Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000744.
     PubMed    
     
     
     
126. KREMER AE, Mayo MJ, Hirschfield GM, Levy C, et al
     Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
     Hepatology. 2023 Dec 20. doi: 10.1097/HEP.0000000000000728.
     PubMed     Abstract available
     
     
     November 2023
127. GHOSH S, Devereaux MW, Liu C, Sokol RJ, et al
     LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition associated cholestasis in mice.
     Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000690.
     PubMed     Abstract available
     
     
     
128. GEHL V, O'Rourke CJ, Andersen JB
     Immunogenomics of cholangiocarcinoma.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000688.
     PubMed     Abstract available
     
     
     
129. HE S, Peng Y, Wei Q
     Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685.
     PubMed    
     
     
     
130. SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al
     Reply - Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
     Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689.
     PubMed    
     
     
     
131. LIU ZP, Sun XH, Yu C, Yin XY, et al
     Letter to the Editor: How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma?
     Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000651.
     PubMed    
     
     
     
132. NIKNEJAD N, Fox D, Burwinkel JL, Zarrin-Khameh N, et al
     ASO silencing of a glycosyltransferase, Poglut1 , improves the liver phenotypes in mouse models of Alagille syndrome.
     Hepatology. 2023;78:1337-1351.
     PubMed     Abstract available
     
     
     
133. YANG F, Hilakivi-Clarke L, Shaha A, Wang Y, et al
     Metabolic reprogramming and its clinical implication for liver cancer.
     Hepatology. 2023;78:1602-1624.
     PubMed     Abstract available
     
     
     October 2023
134. RATTI F, Marino R, Groot Koerkamp B, Aldrighetti L, et al
     Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma".
     Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000659.
     PubMed    
     
     
     
135. SELLERS ZM, Assis DN, Paranjape SM, Sathe M, et al
     Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations.
     Hepatology. 2023 Oct 26. doi: 10.1097/HEP.0000000000000646.
     PubMed     Abstract available
     
     
     
136. HU YF, Ma WJ, Jin YW, Li FY, et al
     Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win.
     Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000634.
     PubMed    
     
     
     
137. 
     Erratum: Modulation of the tryptophan hydroxylase 1/monoamine oxidase-A/5-hydroxytryptamine/5-hydroxytryptamine receptor 2A/2B/2C axis regulates biliary proliferation and liver fibrosis during cholestasis.
     Hepatology. 2023;78:E86.
     PubMed    
     
     
     September 2023
138. GELLERT-KRISTENSEN H, Bojesen SE, Tybjaerg-Hansen A, Stender S, et al
     Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000608.
     PubMed     Abstract available
     
     
     
139. ZHUANG Y, Ortega-Ribera M, Thevkar Nagesh P, Joshi R, et al
     Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
     Hepatology. 2023 Sep 19. doi: 10.1097/HEP.0000000000000611.
     PubMed     Abstract available
     
     
     
140. SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
     Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry.
     Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
     PubMed     Abstract available
     
     
     August 2023
141. PEISELER M, Tacke F
     Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease.
     Hepatology. 2023 Aug 22. doi: 10.1097/HEP.0000000000000576.
     PubMed    
     
     
     
142. RATTI F, Marino R, Olthof PB, Pratschke J, et al
     Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
     Hepatology. 2023 Aug 3. doi: 10.1097/HEP.0000000000000554.
     PubMed     Abstract available
     
     
     
143. DE MUYNCK K, Heyerick L, De Ponti FF, Vanderborght B, et al
     Osteopontin characterizes bile duct associated macrophages and correlates with liver fibrosis severity in primary sclerosing cholangitis.
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000557.
     PubMed     Abstract available
     
     
     
144. BOWLUS CL, Levy C
     Optimizing treatment of primary biliary cholangitis: Is good, good enough?
     Hepatology. 2023 Aug 2. doi: 10.1097/HEP.0000000000000556.
     PubMed    
     
     
     July 2023
145. ZHAO L, Liu J, Li K, Zhang C, et al
     PTPN9 dephosphorylates FGFR2pY656/657 via interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
     Hepatology. 2023 Jul 27. doi: 10.1097/HEP.0000000000000552.
     PubMed     Abstract available
     
     
     
146. LI Y, Li B, Xiao X, Qian Q, et al
     Itaconate inhibits CD103+ TRM cells and alleviates hepatobiliary injury in mouse models of primary sclerosing cholangitis.
     Hepatology. 2023 Jul 26. doi: 10.1097/HEP.0000000000000549.
     PubMed     Abstract available
     
     
     
147. EDELINE J, Bridgewater J, Campillo-Gimenez B, Neveu E, et al
     Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials.
     Hepatology. 2023 Jul 25. doi: 10.1097/HEP.0000000000000544.
     PubMed     Abstract available
     
     
     
148. 
     Retraction: Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
     Hepatology. 2023 Jul 21. doi: 10.1097/HEP.0000000000000484.
     PubMed    
     
     
     
149. JEONG H, Yoo C
     Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial - author's reply.
     Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000535.
     PubMed    
     
     
     
150. HU YF, Gu HF, Jin YW, Li FY, et al
     Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
     Hepatology. 2023 Jul 17. doi: 10.1097/HEP.0000000000000532.
     PubMed    
     
     
     June 2023
151. SOKOL RJ, Gonzales EM, Kamath BM, Baker A, et al
     Predictors of 6-year event-free survival in alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
     Hepatology. 2023 Jun 7. doi: 10.1097/HEP.0000000000000502.
     PubMed     Abstract available
     
     
     
152. EKSER B, Sucu S, Mihaylov P, Emamaullee JA, et al
     Letter to the Editor mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation: Are there other challenges?
     Hepatology. 2023 Jun 5. doi: 10.1097/HEP.0000000000000503.
     PubMed    
     
     
     May 2023
153. NEJAK-BOWEN K, Monga SP
     Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
     Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
     PubMed     Abstract available
     
     
     
154. 
     Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
     Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
     PubMed    
     
     
     
155. SHU L, Li X, Liu Z, Li K, et al
     Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
     Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437.
     PubMed     Abstract available
     
     
     
156. JEONG H, Kim KP, Jeong JH, Hwang DW, et al
     Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
     Hepatology. 2023;77:1540-1549.
     PubMed     Abstract available
     
     
     
157. FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al
     Reply: Living donor liver transplantation for people with PSC.
     Hepatology. 2023;77:E97-E98.
     PubMed    
     
     
     April 2023
158. MACKOWIAK B, Gao B
     Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
     Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416.
     PubMed    
     
     
     
159. RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al
     Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial repair in biliary atresia.
     Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418.
     PubMed     Abstract available
     
     
     
160. DANIEL N, Genua F, Jenab M, Mayen AL, et al
     The role of the gut microbiome in the development of hepatobiliary cancers.
     Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
     PubMed     Abstract available
     
     
     
161. HARTL L, Reiberger T, Trauner M
     Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
     Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
     PubMed    
     
     
     
162. UMAR S, Nadeem A, Nadeem M
     Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
     Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
     PubMed    
     
     
     
163. HIRSCHFIELD GM, Shiffman ML, Gulamhusein A, Kowdley KV, et al
     Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
     Hepatology. 2023 Apr 6. doi: 10.1097/HEP.0000000000000395.
     PubMed     Abstract available
     
     
     
164. YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al
     Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
     Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365.
     PubMed     Abstract available
     
     
     
165. CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al
     A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans.
     Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376.
     PubMed     Abstract available
     
     
     
166. SINGH SP, Mondia N
     Letter to the Editor: Much more needed in natural history of Alagille syndrome.
     Hepatology. 2023;77:E78.
     PubMed    
     
     
     January 2023
167. CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al
     Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206.
     PubMed     Abstract available
     
     
     
168. HEINEMANN M, Adam R, Karam V, Schramm C, et al
     Letter to the Editor: Living donor liver transplantation for people with PSC.
     Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum